Evaluation of vancomycin and gentamicin dialysis clearance using in vivo and in vitro systems

Nathan A. Pinner, Robert B. Canada, Joyce Broyles, Joanna Laizure

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Advances in hemodialysis (HD) techniques have increased the potential for drug removal. Quantifying drug clearance in clinical studies for all possible dialysis conditions is impractical, given the variability in dialysis conditions. The purpose of this study was to determine the dialysis clearance (CLD) of vancomycin and gentamicin using in vitro and in vivo methods and evaluate the applicability of in vitro data. In vitro dialysis was used to determine the CLD of vancomycin and gentamicin under conditions of intermittent HD (IHD) and sustained low-efficiency dialysis (SLED). Two Fresenius polysulfone dialyzers were studied: F180NR for IHD and F50 for SLED. Data were compared with in vivo CLD determined in patients with end-stage renal disease receiving IHD and from the literature for SLED. Under IHD conditions, in vitro CLD of vancomycin and gentamicin was 131 ± 3 and 154 ± 3 mL/min, respectively, and under SLED condition it was 72 ± 9 and 84 ± 11 mL/min, respectively. These values were 11-27% higher than in vivo CLD for IHD (103 ± 15 mL/min for vancomycin and 132 ± 25 mL/min for gentamicin) and SLED (63 mL/min for vancomycin and 76 ± 38 mL/min for gentamicin). There was a statistically significant difference in vancomycin clearance by IHD for the in vitro study compared with in vivo data (p = 0.012), but not for gentamicin (p = 0.18). In vitro methods overestimated in vivo CLD, but are reasonable to assist with drug regimen design if one considers the limitations.

Original languageEnglish (US)
Pages (from-to)703-707
Number of pages5
JournalRenal Failure
Volume34
Issue number6
DOIs
StatePublished - Jul 1 2012

Fingerprint

Vancomycin
Gentamicins
Dialysis
Renal Dialysis
In Vitro Techniques
Drug Design
Pharmaceutical Preparations
Chronic Kidney Failure

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine
  • Nephrology

Cite this

Evaluation of vancomycin and gentamicin dialysis clearance using in vivo and in vitro systems. / Pinner, Nathan A.; Canada, Robert B.; Broyles, Joyce; Laizure, Joanna.

In: Renal Failure, Vol. 34, No. 6, 01.07.2012, p. 703-707.

Research output: Contribution to journalArticle

@article{8a7e7e963c93430dbbb7815cbaf530be,
title = "Evaluation of vancomycin and gentamicin dialysis clearance using in vivo and in vitro systems",
abstract = "Advances in hemodialysis (HD) techniques have increased the potential for drug removal. Quantifying drug clearance in clinical studies for all possible dialysis conditions is impractical, given the variability in dialysis conditions. The purpose of this study was to determine the dialysis clearance (CLD) of vancomycin and gentamicin using in vitro and in vivo methods and evaluate the applicability of in vitro data. In vitro dialysis was used to determine the CLD of vancomycin and gentamicin under conditions of intermittent HD (IHD) and sustained low-efficiency dialysis (SLED). Two Fresenius polysulfone dialyzers were studied: F180NR for IHD and F50 for SLED. Data were compared with in vivo CLD determined in patients with end-stage renal disease receiving IHD and from the literature for SLED. Under IHD conditions, in vitro CLD of vancomycin and gentamicin was 131 ± 3 and 154 ± 3 mL/min, respectively, and under SLED condition it was 72 ± 9 and 84 ± 11 mL/min, respectively. These values were 11-27{\%} higher than in vivo CLD for IHD (103 ± 15 mL/min for vancomycin and 132 ± 25 mL/min for gentamicin) and SLED (63 mL/min for vancomycin and 76 ± 38 mL/min for gentamicin). There was a statistically significant difference in vancomycin clearance by IHD for the in vitro study compared with in vivo data (p = 0.012), but not for gentamicin (p = 0.18). In vitro methods overestimated in vivo CLD, but are reasonable to assist with drug regimen design if one considers the limitations.",
author = "Pinner, {Nathan A.} and Canada, {Robert B.} and Joyce Broyles and Joanna Laizure",
year = "2012",
month = "7",
day = "1",
doi = "10.3109/0886022X.2012.672153",
language = "English (US)",
volume = "34",
pages = "703--707",
journal = "Renal Failure",
issn = "0886-022X",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Evaluation of vancomycin and gentamicin dialysis clearance using in vivo and in vitro systems

AU - Pinner, Nathan A.

AU - Canada, Robert B.

AU - Broyles, Joyce

AU - Laizure, Joanna

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Advances in hemodialysis (HD) techniques have increased the potential for drug removal. Quantifying drug clearance in clinical studies for all possible dialysis conditions is impractical, given the variability in dialysis conditions. The purpose of this study was to determine the dialysis clearance (CLD) of vancomycin and gentamicin using in vitro and in vivo methods and evaluate the applicability of in vitro data. In vitro dialysis was used to determine the CLD of vancomycin and gentamicin under conditions of intermittent HD (IHD) and sustained low-efficiency dialysis (SLED). Two Fresenius polysulfone dialyzers were studied: F180NR for IHD and F50 for SLED. Data were compared with in vivo CLD determined in patients with end-stage renal disease receiving IHD and from the literature for SLED. Under IHD conditions, in vitro CLD of vancomycin and gentamicin was 131 ± 3 and 154 ± 3 mL/min, respectively, and under SLED condition it was 72 ± 9 and 84 ± 11 mL/min, respectively. These values were 11-27% higher than in vivo CLD for IHD (103 ± 15 mL/min for vancomycin and 132 ± 25 mL/min for gentamicin) and SLED (63 mL/min for vancomycin and 76 ± 38 mL/min for gentamicin). There was a statistically significant difference in vancomycin clearance by IHD for the in vitro study compared with in vivo data (p = 0.012), but not for gentamicin (p = 0.18). In vitro methods overestimated in vivo CLD, but are reasonable to assist with drug regimen design if one considers the limitations.

AB - Advances in hemodialysis (HD) techniques have increased the potential for drug removal. Quantifying drug clearance in clinical studies for all possible dialysis conditions is impractical, given the variability in dialysis conditions. The purpose of this study was to determine the dialysis clearance (CLD) of vancomycin and gentamicin using in vitro and in vivo methods and evaluate the applicability of in vitro data. In vitro dialysis was used to determine the CLD of vancomycin and gentamicin under conditions of intermittent HD (IHD) and sustained low-efficiency dialysis (SLED). Two Fresenius polysulfone dialyzers were studied: F180NR for IHD and F50 for SLED. Data were compared with in vivo CLD determined in patients with end-stage renal disease receiving IHD and from the literature for SLED. Under IHD conditions, in vitro CLD of vancomycin and gentamicin was 131 ± 3 and 154 ± 3 mL/min, respectively, and under SLED condition it was 72 ± 9 and 84 ± 11 mL/min, respectively. These values were 11-27% higher than in vivo CLD for IHD (103 ± 15 mL/min for vancomycin and 132 ± 25 mL/min for gentamicin) and SLED (63 mL/min for vancomycin and 76 ± 38 mL/min for gentamicin). There was a statistically significant difference in vancomycin clearance by IHD for the in vitro study compared with in vivo data (p = 0.012), but not for gentamicin (p = 0.18). In vitro methods overestimated in vivo CLD, but are reasonable to assist with drug regimen design if one considers the limitations.

UR - http://www.scopus.com/inward/record.url?scp=84862178190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862178190&partnerID=8YFLogxK

U2 - 10.3109/0886022X.2012.672153

DO - 10.3109/0886022X.2012.672153

M3 - Article

VL - 34

SP - 703

EP - 707

JO - Renal Failure

JF - Renal Failure

SN - 0886-022X

IS - 6

ER -